Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Investigation for the presence of asthma comorbidities is recommended by the Global Initiative for Asthma because their presence can complicate asthma management.
OBJECTIVE: To understand the prevalence and pattern of comorbidities and multimorbidity in adults with severe asthma and their association with asthma-related outcomes.
METHODS: This was a cross-sectional study using data from the International Severe Asthma Registry from 22 countries. A total of 30 comorbidities were identified and categorized a priori as any of the following: (1) potentially type 2-related comorbidities, (2) potentially oral corticosteroid (OCS)-related comorbidities, or (3) comorbidities mimicking or aggravating asthma. The association between comorbidities and asthma-related outcomes was investigated using multivariable models adjusted for country, age at enrollment, and sex (ie male or female).
RESULTS: Of the 11,821 patients, 69%, 67%, and 55% had at least 1 potentially type 2-related, potentially OCS-related, or mimicking or aggravating comorbidities, respectively; 57% had 3 or more comorbidities, and 33% had comorbidities in all 3 categories. Patients with allergic rhinitis, nasal polyposis, and chronic rhinosinusitis experienced 1.12 (P = .003), 1.16 (P < .001), and 1.29 times (P < .001) more exacerbations per year, respectively, than those without. Patients with nasal polyposis and chronic rhinosinusitis were 40% and 46% more likely (P < .001), respectively, to have received long-term (LT) OCS. All assessed potential OCS-related comorbidities (except obesity) were associated with a greater likelihood of LTOCS use (odds ratios [ORs]: 1.23-2.77) and, except for dyslipidemia, with a greater likelihood of uncontrolled asthma (ORs: 1.29-1.68). All mimicking or aggravating comorbidities assessed were associated with more exacerbations (1.24-1.68 times more), all (except bronchiectasis) with increased likelihood of uncontrolled asthma (ORs: 1.57-1.81), and all (except chronic obstructive pulmonary disease) with increased likelihood of LTOCS use (ORs: 1.37-1.57). A greater number of comorbidities was associated with worse outcomes.
CONCLUSION: In a global study, comorbidity or multimorbidity is reported in most adults with severe asthma and is associated with poorer asthma-related outcomes.
CLINICAL TRIAL REGISTRATION: The International Severe Asthma Registry database has ethical approval from the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218) and is registered with the European Union Electronic Register of Post-Authorization Studies (European Network Centres for Pharmacoepidemiology and Pharmacovigilance [ENCEPP]/DSPP/23720). The study was designed, implemented, and reported in compliance with the European Network Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Code of Conduct (EMA 2014; EUPAS44024) and with all applicable local and international laws and regulations, and registered with ENCEPP (https://www.encepp.eu/encepp/viewResource.htm?id=48848). Governance was provided by ADEPT (registration number: ADEPT1121).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 2023 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology - 132(2023), 1 vom: 21. Jan., Seite 42-53 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.anai.2023.08.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361383614 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361383614 | ||
| 003 | DE-627 | ||
| 005 | 20231227135850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.anai.2023.08.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM361383614 | ||
| 035 | |a (NLM)37640263 | ||
| 035 | |a (PII)S1081-1206(23)00630-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Scelo, Ghislaine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Investigation for the presence of asthma comorbidities is recommended by the Global Initiative for Asthma because their presence can complicate asthma management | ||
| 520 | |a OBJECTIVE: To understand the prevalence and pattern of comorbidities and multimorbidity in adults with severe asthma and their association with asthma-related outcomes | ||
| 520 | |a METHODS: This was a cross-sectional study using data from the International Severe Asthma Registry from 22 countries. A total of 30 comorbidities were identified and categorized a priori as any of the following: (1) potentially type 2-related comorbidities, (2) potentially oral corticosteroid (OCS)-related comorbidities, or (3) comorbidities mimicking or aggravating asthma. The association between comorbidities and asthma-related outcomes was investigated using multivariable models adjusted for country, age at enrollment, and sex (ie male or female) | ||
| 520 | |a RESULTS: Of the 11,821 patients, 69%, 67%, and 55% had at least 1 potentially type 2-related, potentially OCS-related, or mimicking or aggravating comorbidities, respectively; 57% had 3 or more comorbidities, and 33% had comorbidities in all 3 categories. Patients with allergic rhinitis, nasal polyposis, and chronic rhinosinusitis experienced 1.12 (P = .003), 1.16 (P < .001), and 1.29 times (P < .001) more exacerbations per year, respectively, than those without. Patients with nasal polyposis and chronic rhinosinusitis were 40% and 46% more likely (P < .001), respectively, to have received long-term (LT) OCS. All assessed potential OCS-related comorbidities (except obesity) were associated with a greater likelihood of LTOCS use (odds ratios [ORs]: 1.23-2.77) and, except for dyslipidemia, with a greater likelihood of uncontrolled asthma (ORs: 1.29-1.68). All mimicking or aggravating comorbidities assessed were associated with more exacerbations (1.24-1.68 times more), all (except bronchiectasis) with increased likelihood of uncontrolled asthma (ORs: 1.57-1.81), and all (except chronic obstructive pulmonary disease) with increased likelihood of LTOCS use (ORs: 1.37-1.57). A greater number of comorbidities was associated with worse outcomes | ||
| 520 | |a CONCLUSION: In a global study, comorbidity or multimorbidity is reported in most adults with severe asthma and is associated with poorer asthma-related outcomes | ||
| 520 | |a CLINICAL TRIAL REGISTRATION: The International Severe Asthma Registry database has ethical approval from the Anonymous Data Ethics Protocols and Transparency (ADEPT) committee (ADEPT0218) and is registered with the European Union Electronic Register of Post-Authorization Studies (European Network Centres for Pharmacoepidemiology and Pharmacovigilance [ENCEPP]/DSPP/23720). The study was designed, implemented, and reported in compliance with the European Network Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP) Code of Conduct (EMA 2014; EUPAS44024) and with all applicable local and international laws and regulations, and registered with ENCEPP (https://www.encepp.eu/encepp/viewResource.htm?id=48848). Governance was provided by ADEPT (registration number: ADEPT1121) | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Torres-Duque, Carlos A |e verfasserin |4 aut | |
| 700 | 1 | |a Maspero, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Trung N |e verfasserin |4 aut | |
| 700 | 1 | |a Murray, Ruth |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Menzies-Gow, Andrew N |e verfasserin |4 aut | |
| 700 | 1 | |a Hew, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Peters, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Gibson, Peter G |e verfasserin |4 aut | |
| 700 | 1 | |a Christoff, George C |e verfasserin |4 aut | |
| 700 | 1 | |a Popov, Todor A |e verfasserin |4 aut | |
| 700 | 1 | |a Côté, Andréanne |e verfasserin |4 aut | |
| 700 | 1 | |a Bergeron, Celine |e verfasserin |4 aut | |
| 700 | 1 | |a Dorscheid, Delbert |e verfasserin |4 aut | |
| 700 | 1 | |a FitzGerald, J Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Kenneth R |e verfasserin |4 aut | |
| 700 | 1 | |a Boulet, Louis Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Bhutani, Mohit |e verfasserin |4 aut | |
| 700 | 1 | |a Sadatsafavi, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Maldonado, Libardo |e verfasserin |4 aut | |
| 700 | 1 | |a Duran-Silva, Mauricio |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriguez, Bellanid |e verfasserin |4 aut | |
| 700 | 1 | |a Celis-Preciado, Carlos Andres |e verfasserin |4 aut | |
| 700 | 1 | |a Cano-Rosales, Diana Jimena |e verfasserin |4 aut | |
| 700 | 1 | |a Solarte, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Sanchez, Maria Jose |e verfasserin |4 aut | |
| 700 | 1 | |a Parada-Tovar, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a von Bülow, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Bjerrum, Anne Sofie |e verfasserin |4 aut | |
| 700 | 1 | |a Ulrik, Charlotte S |e verfasserin |4 aut | |
| 700 | 1 | |a Assing, Karin Dahl |e verfasserin |4 aut | |
| 700 | 1 | |a Rasmussen, Linda Makowska |e verfasserin |4 aut | |
| 700 | 1 | |a Hansen, Susanne |e verfasserin |4 aut | |
| 700 | 1 | |a Altraja, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Bourdin, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Taille, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Charriot, Jeremy |e verfasserin |4 aut | |
| 700 | 1 | |a Roche, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Papaioannou, Andriana I |e verfasserin |4 aut | |
| 700 | 1 | |a Kostikas, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Papadopoulos, Nikolaos G |e verfasserin |4 aut | |
| 700 | 1 | |a Salvi, Sundeep |e verfasserin |4 aut | |
| 700 | 1 | |a Long, Deirdre |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Patrick D |e verfasserin |4 aut | |
| 700 | 1 | |a Costello, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Sirena, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Cardini, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Heffler, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Puggioni, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Canonica, Giorgio Walter |e verfasserin |4 aut | |
| 700 | 1 | |a Guida, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Iwanaga, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Ahmad, Mona |e verfasserin |4 aut | |
| 700 | 1 | |a Linnemann, Désirée Larenas |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Ulises |e verfasserin |4 aut | |
| 700 | 1 | |a Kuna, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, João A |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Lehebi, Riyad |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, Mariko Siyue |e verfasserin |4 aut | |
| 700 | 1 | |a Rhee, Chin Kook |e verfasserin |4 aut | |
| 700 | 1 | |a Cosio, Borja G |e verfasserin |4 aut | |
| 700 | 1 | |a de Llano, Luis Perez |e verfasserin |4 aut | |
| 700 | 1 | |a Perng Steve, Diahn-Warng |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Erick Wan-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hao-Chien |e verfasserin |4 aut | |
| 700 | 1 | |a Tsai, Ming-Ju |e verfasserin |4 aut | |
| 700 | 1 | |a Mahboub, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Salameh, Laila Ibraheem Jaber |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, David |e verfasserin |4 aut | |
| 700 | 1 | |a Busby, John |e verfasserin |4 aut | |
| 700 | 1 | |a Heaney, Liam G |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeffer, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Goddard, Amanda Grippen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Eileen |e verfasserin |4 aut | |
| 700 | 1 | |a Hoyte, Flavia |e verfasserin |4 aut | |
| 700 | 1 | |a Wechsler, Michael E |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Katial, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Bulathsinhala, Lakmini |e verfasserin |4 aut | |
| 700 | 1 | |a Eleangovan, Neva |e verfasserin |4 aut | |
| 700 | 1 | |a Ariti, Con |e verfasserin |4 aut | |
| 700 | 1 | |a Lyu, Juntao |e verfasserin |4 aut | |
| 700 | 1 | |a Price, David B |e verfasserin |4 aut | |
| 700 | 1 | |a Porsbjerg, Celeste |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology |d 1995 |g 132(2023), 1 vom: 21. Jan., Seite 42-53 |w (DE-627)NLM075127695 |x 1534-4436 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2023 |g number:1 |g day:21 |g month:01 |g pages:42-53 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.anai.2023.08.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2023 |e 1 |b 21 |c 01 |h 42-53 | ||